Statement of Beneficial Ownership (sc 13d)
October 10 2017 - 9:00AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE
13D
Under
the Securities Exchange Act of 1934 (Amendment No. __)
Roka
Bioscience, Inc
|
(Name
of Issuer)
|
Common
Shares
|
(Title
of Class of Securities)
|
Edward
Painter, 544 King St Chappaqua NY 10514, 914 841 8818
|
(Name,
Address and Telephone Number of Person Authorized to Receive Notices and Communications)
|
|
September
29, 2017
|
(Date
of Event which Requires Filing of this Statement)
|
If
the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule
13D, and is filing this schedule because of 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ☐.
Note:
Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See 240.13d-7(b)
for other parties to whom copies are to be sent.
*The
remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the
subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in
a prior cover page.
The
information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section
18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the Notes).
Page
2
SCHEDULE
13D
1
|
NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
|
Edward Painter
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
|
(a) ☐
(b) ☐
|
3
|
SEC USE ONLY
|
|
4
|
SOURCE OF FUNDS (See Instructions)
|
Personal Funds
|
5
|
CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E)
☐
|
|
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
|
USA
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
|
7
|
SOLE VOTING POWER
|
340,000
|
8
|
SHARED VOTING POWER
|
|
9
|
SOLE DISPOSITIVE POWER
|
340,000
|
10
|
SHARED DISPOSITIVE POWER
|
|
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
340,000
|
12
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) ☐
|
|
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
|
6.79%
|
14
|
TYPE OF REPORTING PERSON (See Instructions)
|
Individual
|
Page 3
|
Item 1.
|
Security and Issuer
|
|
Item 2.
|
Identity and Background
|
|
(b)
|
544 King St, Chappaqua NY 10514
|
|
(c)
|
Founder & CEO A2A Pharmaceuticals
|
|
Item 3.
|
Source and Amount of Funds or Other Considerations
|
Personal funds
|
Item 4.
|
Purpose of Transaction
|
Edward Painter purchased shares with the
intention of seeking a business combination with A2A Pharmaceuticals, a private biotechnology company. He may sell shares or buy
additional shares or change his purpose of transacting in the future.
|
Item 5.
|
Interest in Securities of the Issuer
|
|
(a)
|
340,000 shares (6.79%)
|
|
(b)
|
340,000 sole power to vote and dispose of
|
|
Item 6.
|
Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.
|
None
|
Item 7.
|
Material to Be Filed as Exhibits
|
None
Page 4
Signature
After reasonable inquiry and to the best
of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
October 9, 2017
|
|
Dated
|
|
|
|
/s/ Edward Painter
|
|
Signature
|
|
|
|
Edward Painter
|
|
Name/Title
|
|
The original statement shall be signed
by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of
a person by his authorized representative (other than an executive officer or general partner of this filing person), evidence
of the representative’s authority to sign on behalf of such person shall be filed with the statement, provided, however,
that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name
and any title of each person who signs the statement shall be typed or printed beneath his signature.
Attention: Intentional misstatements
or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).
ROKA BIOSCIENCE, INC. (NASDAQ:ROKA)
Historical Stock Chart
From Mar 2024 to Apr 2024
ROKA BIOSCIENCE, INC. (NASDAQ:ROKA)
Historical Stock Chart
From Apr 2023 to Apr 2024